Author:
Akita Tomomi,Morita Yuki,Kawai Takehiro,Oda Kazuaki,Tange Kota,Nakai Yuta,Yamashita Chikamasa
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by chronic bronchitis and emphysema, and current drug treatments target its symptoms. Thus, the development of a therapeutic drug to repair alveolar destruction is urgently needed. Our previous research revealed that the synthetic retinoic acid Am80 (1.0 mg/kg) showed a repairing effect on collapsed alveoli in a mouse model of elastase-induced emphysema. However, a further reduction in the dose is desirable to facilitate the development of a powder inhalation formulation for clinical application. We, therefore, focused on SS-OP to deliver Am80 efficiently. As a result, 0.01 mg/kg of Am80-encapsulated SS-OP nanoparticles repaired collapsed alveoli and improved the respiratory function in the mouse model of elastase induced emphysema. The results suggested that, with the use of SS-OP, the Am80 dose could be reduced. This could contribute to the development of a powder inhalation system as a curative medicine for COPD.
Reference43 articles.
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive summary;Pauwels;Respir. Care,2001
2. Early life origins of chronic obstructive pulmonary disease;Svanes;Thorax,2010
3. Asthma and chronic obstructive pulmonary disease: Common genes, common environments?;Postma;Am. J. Respir. Crit. Care Med.,2011
4. The danger signal plus DNA damage two-hit hypothesis for chronic inflammation in COPD;Aoshiba;Eur. Respir. J.,2013
5. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease;Lange;N. Engl. J. Med.,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献